ACE-031 (1mg)

ACE-031 (1mg) is an experimental recombinant fusion protein designed for laboratory research involving the activin receptor type IIB (ActRIIB), myostatin signaling, activin biology, skeletal muscle regulation, and related pathways within the transforming growth factor-beta (TGF-β) superfamily. This 1mg research quantity is intended for qualified laboratory and scientific investigations where controlled characterization of ActRIIB-related signaling is required. 

ACE-031 has attracted scientific interest because of its ability to interact with myostatin and other ligands involved in the regulation of muscle biology. Research has investigated ACE-031 in preclinical models as well as clinical studies, making it a notable compound for researchers examining receptor-ligand interactions, muscle-growth pathways, and experimental therapeutic strategies.

Important: ACE-031 is an investigational research compound and is not an approved human medicine. Clinical investigation was discontinued after safety concerns, including epistaxis and telangiectasias, were observed in a Duchenne muscular dystrophy study.

ACE-031 (1mg) Product Overview

ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB). Structurally, it is a fusion protein consisting of the extracellular portion of human ActRIIB linked to the Fc portion of human IgG1. This design allows researchers to investigate ligand sequestration and signaling pathways associated with ActRIIB.

Unlike conventional small-molecule research compounds, ACE-031 is a biologically active recombinant protein. Its molecular characteristics make appropriate laboratory handling, validated analytical methods, controlled storage, and documented experimental procedures particularly important.

The 1mg quantity is a product amount for research planning and is not a recommended human dose.

Ingredients

The primary active research material is:

• ACE-031 recombinant fusion protein – 1mg

ACE-031 consists of the ActRIIB extracellular domain fused to human IgG1 Fc. The precise formulation, buffer components, stabilizers, or other excipients can vary according to the manufacturer’s specification. Researchers should consult the product’s Certificate of Analysis (COA) and accompanying documentation for the exact formulation.

ACE-031 Research Applications

ACE-031 is particularly relevant to researchers studying pathways associated with myostatin, activin signaling, ActRIIB, skeletal muscle biology, and TGF-β superfamily signaling.

Potential laboratory research areas include:

Myostatin Signaling Research

Myostatin, also known as growth differentiation factor-8 (GDF-8), is involved in regulating skeletal muscle development and maintenance. ACE-031 has been investigated as an ActRIIB-based approach for interacting with myostatin and related ligands.

ActRIIB Ligand Research

Researchers can use ACE-031 as a model system for investigating interactions between soluble ActRIIB and ligands within the TGF-β superfamily.

Skeletal Muscle Biology

Preclinical research has examined soluble ActRIIB-based approaches in relation to muscle mass and muscle characteristics. Earlier animal research reported increases in skeletal muscle measurements following ACE-031-related treatment, providing a foundation for further mechanistic investigation.

Translational Research

ACE-031 has been investigated in both experimental and clinical research settings. More recent non-human-primate research has also examined ACE-031 in relation to skeletal muscle mass and function. These findings remain research observations and should not be interpreted as evidence of an approved human treatment.

ACE-031 (1mg) Research Concentration & Dosage Framework

Because ACE-031 is an experimental biologically active protein, there is no appropriate universal human dosage guide for this product. Published clinical-study doses should not be converted into personal-use instructions, and the 1mg package quantity should not be interpreted as a dosage recommendation.

For laboratory researchers, the appropriate calculation depends on the validated experimental protocol, assay requirements, sample volume, and desired concentration.

A general research calculation is:

Required ACE-031 amount = Target experimental concentration × Final experimental volume

For example, if a validated laboratory protocol specifies a particular target concentration, researchers can calculate the required amount from that concentration and the final experimental volume. Any dilution, preparation, or concentration selection should follow the validated protocol applicable to the specific experiment and material.

Researchers should document:

• Target experimental concentration,
• Final experimental volume,
• Required ACE-031 quantity,
• Experimental model,
• Assay conditions,
• Exposure period,
• Appropriate controls,
• Storage conditions,
• Lot or batch number,
• COA and analytical documentation.

Do not extrapolate animal or historical clinical-study dosing to human self-administration.

Why Choose ACE-031 (1mg) for Research?

Researchers looking for ACE-031 1mg, ACE-031 research protein, or ACE-031 recombinant protein can use this product format when a controlled quantity of ActRIIB-related research material is required.

The 1mg format can be useful for laboratory projects involving receptor-ligand biology, protein characterization, myostatin-related research, and experimental signaling studies. Researchers should evaluate product documentation, analytical testing, purity information, and batch-specific specifications before beginning an experiment.

For research procurement, important documentation may include a Certificate of Analysis (COA), batch information, purity data, storage recommendations, and product specifications.

ACE-031 Research Quality Considerations

When sourcing ACE-031 for laboratory research, quality documentation is an important part of responsible experimental planning. Researchers should verify the identity of the material, batch information, analytical characterization, purity specifications, and storage requirements.

Because ACE-031 is a recombinant fusion protein, laboratory researchers should use procedures appropriate for biologically active proteins and maintain suitable documentation throughout the experimental workflow.

Frequently Asked Questions

What is ACE-031 (1mg)?

ACE-031 (1mg) is a research quantity of ACE-031, an experimental soluble ActRIIB-based fusion protein investigated in connection with myostatin and related TGF-β superfamily signaling.

Is ACE-031 a peptide?

ACE-031 is more accurately described as a recombinant fusion protein, rather than a conventional short peptide. It contains the extracellular portion of ActRIIB fused to an IgG1 Fc region.

What is ACE-031 used for?

ACE-031 has been investigated experimentally in research involving ActRIIB signaling, myostatin, activin-related pathways, skeletal muscle biology, and related molecular mechanisms. It is intended here strictly as research material.

Is ACE-031 approved for human use?

No. ACE-031 has not been approved as a human therapeutic. Clinical development encountered safety concerns, including epistaxis and telangiectasias.

Does 1mg mean one human dose?

No. 1mg describes the quantity of research material in the product and is not a human dosing recommendation.

Order ACE-031 (1mg) for Laboratory Research

ACE-031 (1mg) provides researchers with a defined quantity of an experimental ActRIIB fusion protein for controlled scientific investigation. Its relevance to myostatin, activin, receptor-ligand interactions, and skeletal muscle signaling makes it a specialized research material for appropriately equipped laboratories.

When purchasing ACE-031 1mg, researchers should prioritize product identity, batch documentation, analytical specifications, COA availability, and appropriate research-use labeling.